Biopharmx Corp., of Menlo Park, Calif., said data of a previously disclosed phase IIb trial testing BPX-01, a topical hydrophilic gel formulation of the antibiotic minocycline, in patients with acne vulgaris will be presented at the Alabama Dermatology Society's Summer Symposium.